iCo Therapeutics (iCo Therapeutics) Cash And Cash Equivalents : $1.67 Mil (As of Mar. 2021)

View and export this data going back to 2009. Start your Free Trial

What is iCo Therapeutics Cash And Cash Equivalents?

iCo Therapeutics's quarterly cash and cash equivalents declined from Sep. 2020 ($0.13 Mil) to Dec. 2020 ($0.05 Mil) but then increased from Dec. 2020 ($0.05 Mil) to Mar. 2021 ($1.67 Mil).

iCo Therapeutics's annual cash and cash equivalents increased from Dec. 2018 ($0.01 Mil) to Dec. 2019 ($0.75 Mil) but then declined from Dec. 2019 ($0.75 Mil) to Dec. 2020 ($0.05 Mil).

iCo Therapeutics Cash And Cash Equivalents Historical Data

The historical data trend for iCo Therapeutics's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

iCo Therapeutics Cash And Cash Equivalents Chart

iCo Therapeutics Annual Data

Trend

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Cash And Cash Equivalents

Get a 7-Day Free Trial

1.77

0.88

0.01

0.75

0.05

iCo Therapeutics Quarterly Data
	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21
Cash And Cash Equivalents	Get a 7-Day Free Trial															0.34	0.27	0.13	0.05	1.67

iCo Therapeutics Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

iCo Therapeutics (GREY:ICOTF) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

iCo Therapeutics Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of iCo Therapeutics's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

iCo Therapeutics (iCo Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » iCo Therapeutics Inc (GREY:ICOTF) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

N/A

Address

777 Hornby Street, 6th Floor, Vancouver, BC, CAN, V6Z 1S4

Website

http://www.icotherapeutics.com

iCo Therapeutics Inc is a Canada based biotechnology company. It is involved in the Research and development of ophthalmic indications. The company identifies, develops, and commercialize drug candidates with clinical history, and re-doses, reformulates and develops these drug candidates to treat sight and life-threatening diseases. Its in-licensed assets are iCo-008 and the Oral AmpB Delivery System. iCo-008 is a human monoclonal antibody targeting eotaxin-1 that acts as a messenger between the cells of the immune system. Geographically, it operates in Canada and Australia.

iCo Therapeutics (iCo Therapeutics) Headlines

No Headlines